Moderna's story is changing fast, but the stock is already pricing in a lot. See what the Phase 3 cancer result really proves ...

Following last month's super rally, a growing number of analysts are now calling for caution.

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rallying again as investors position ahead of a late-October data drop that could validate the first personalized cancer therapy tested at ...

A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual ...

Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected ...

Merck and Moderna build a custom mRNA vaccine for each melanoma patient from tumor mutations. The strategy stumbles in cancers lacking enough targets ...

But what has the stock done for shareholders lately? How has it done over the past five years? Not so great. It has averaged annual losses over that period -- enough to turn a single $10,000 ...

Click here for the report explaining the August 24th YouTube video!Large-scale clinical trial data has been released ...

Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P 500 gained 18.5% with dividends reinvested over the same window, and Pfizer ...

The biotech giant posted positive trial results of a cancer vaccine, boosting shares at a record-setting pace before investors pulled back.

After years of layoffs, cash burn and political attacks on its core technology, Moderna’s melanoma vaccine data notched the biotech company a much-needed win.

That came after Moderna and Merck announced their personalized cancer vaccine helped cut the recurrence of melanoma—a form of skin cancer—in a late-stage trial involving more than 1,100 patients, and ...